Study shows Picato (Leo Pharma) provides sustained clearance of Actinic Keratosis at 12 months
Results of long-term clearance rates of Actinic Keratosis lesions after treatment with Picato (ingenol mebutate gel), from Leo Pharma, demonstrated that patients showing sustained complete clearance at 12 months, was 46 per cent (n=108) on the face and scalp and 44 per cent (n=76) on the trunk or extremities.
The secondary outcome showed that patients in the overall population experienced approximately 87 per cent reduction in the original number of actinic keratoses in the treated area of skin. Results have been published in JAMA Dermatology. Ingenol mebutate gel was approved by the FDA in January 2012; by the Therapeutic Goods Administration in Australia and European Commission in Europe in November 2012. See: "Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses." Mark Lebwohl et al. JAMA Dermatol. 2013;():1-5. doi:10.1001/jamadermatol.2013.2766.
Related news and insights
SpringWorks Therapeutics, Inc. announced that the FDA has approved Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors who require systemic treatment
Protagonist Therapeutics, Inc. announced two additional Phase III studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ 2113 (formerly PN 235) in head-to-head comparisons against deucravacitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe psoriasis
Biotronik announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress